WASHINGTON, D.C. – U.S. Sen. Sherrod Brown (D-OH) applauded a proposal issued today by the Drug Enforcement Administration (DEA) to reduce the production of prescription opioids by 20 percent next year. The DEA is responsible for establishing annual quotas determining the exact amount of each opioid drug that is permitted to be produced in the U.S. each year. Brown asked the agency to take this step.
“We all have a role to play in combatting the opioid epidemic and this step shows DEA is committed to playing its part in our efforts,” said Brown. “Of course there is still more for us to do – from investing in communities on the frontlines of the epidemic to stopping illegal shipments of drugs at our borders.”
Yesterday, Brown and several of his Senate colleagues met with Chuck Rosenberg, Acting Administrator at the Drug Enforcement Administration (DEA), and urged him to reduce the amount of opioid pills allowed to be manufactured and sold in the United States in 2018.
In July, Brown joined a group of sixteen senators in urging the DEA to better prevent painkillers from flooding the market by setting lower opioid production quotas for 2018. The senators also pressed the agency to improve transparency in its quota-setting process by providing an explanation of how it reaches a determination and publishing quotas granted to individual manufacturers of opioids. Today, the DEA announced a proposal to cut the amount of prescription opioids manufactured in the U.S. by 20 percent. Brown’s efforts in 2016 were also effective, resulting in a 25 percent cut for 2017.
Just this week, Brown applauded several recommendations from the Administration’s Commission on Combating Drug Addiction and the Opioid Crisis. Several of the Commission’s recommendations are proposals Brown has worked on, including: